ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BRVE / forecast
TRVI (30) XERS (64) SLS (38) SRPT (27) ⌘ Pro Terminal →

Braveheart Bio Inc. (BRVE) 12-Month Stock Forecast & Price Target Cone

$21.04 -2.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.92

Braveheart Bio Inc. (BRVE) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.94B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BRVE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Braveheart Bio Inc. (NASDAQ: BRVE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $21.04 (-2.18% 1D, market cap $1.94B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BRVE ranks #325 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BRVE compare to TRVI and XERS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BRVE carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TRVI (Trevi Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -23.7%, cap $1.93B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, BRVE leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BRVE?
▼

Per BRVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002131524), Braveheart Bio Inc. generated $37.5M in revenue, $0 in net income, and $0 in free cash flow against $89.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.92 (-0.58%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 144.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (5)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
$34 Bull$20 Base$16 Bear
📬 FREE BRVE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BRVE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY BRVE SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 144.5% FCF Margin ($54.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$19.33+4.9% Next Q
Q2 (-2Q)
41
Grade D$20.27+7.6% Next Q
Q3 (-1Q)
43
Grade D$21.82-3.6% Next Q
Current
46
Grade D$21.04-6.1% Hist 90D α
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BRVE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BRVE currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.27) and Max Pain ($22.09) forces dealer call-delta covering toward $33.60.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BRVE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BRVE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BRVE Position Size: $10,000

Shares at $21.04: 475.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $15.52
$7,376
$-2,624 (-26.2%)
12M Consensus BaseTarget $19.90
$9,458
$-542 (-5.4%)
12M Bull Case BreakoutTarget $33.60
$15,970
+$5,970 (+59.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$2174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$3269%B
JP MorganUS Large-Cap ResearchSELL$1858%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BRVE)

  • ✓Walkthrough of BRVE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BRVE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.40%▼ DESCENDING CHANNEL
2026-11-03O $21.19H $21.51L $21.04C $21.04VOL 533.7K
RES: $26.64SUP: $13.56SMA50: $23.27SMA200: $24.14
$32.99$28.89$24.79$20.69$16.59RES $26.64SUP $13.56$21.042026-08-062026-08-272026-09-212026-10-122026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BRVE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BRVE Butterfly Map → + Track BRVE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BRVE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BRVE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BRVE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BRVE)

Health Care Rank #325 of 1015 ⚔️ TRVI vs BRVE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BRVE vs. TRVI, XERS, SLS, SRPT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Braveheart Bio Inc. (BRVE) ranks #325 by composite RQD confidence (46/100, grade D) and #260 by equity capitalization ($1.94B). Within this direct 5-issuer industry benchmark cohort, BRVE leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with BRVE at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BRVE ACTIVE
Braveheart Bio Inc.
D 46/100 — — — -2.18% $1.94B Benchmark Subject
TRVI
Trevi Therapeutics Inc.
E 30/100 — — -23.7% +0.52% $1.93B /trvi-vs-brve →
XERS
Xeris Biopharma Holdings Inc.
C 64/100 — — 16.0% -5.04% $1.95B /xers-vs-brve →
SLS
SELLAS Life Sciences Group Inc.
D- 38/100 — — -21.8% -11.67% $1.95B /sls-vs-brve →
SRPT
Sarepta Therapeutics Inc.
E 27/100 — 96.0% -35.0% -1.61% $1.97B /srpt-vs-brve →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002131524 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Braveheart Bio Inc. (BRVE) reported GAAP revenue of $37.5M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BRVE closed FY2025 with $89.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $37.5M $0 — — $89.3M —

3. BRVE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Braveheart Bio Inc. (NASDAQ: BRVE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $21.04 (-2.18% 1D, market cap $1.94B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BRVE ranks #325 in composite RQD confidence.

How does BRVE compare to TRVI and XERS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BRVE carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TRVI (Trevi Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -23.7%, cap $1.93B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, BRVE leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BRVE?

Per BRVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002131524), Braveheart Bio Inc. generated $37.5M in revenue, $0 in net income, and $0 in free cash flow against $89.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BRVE trading relative to its 50-day, 200-day, and 52-week technical levels?

BRVE last traded at $21.04 (-2.18% on volume of 260,135 shares), positioning the stock -9.58% below its 50-day simple moving average ($23.27) and -12.84% below its 200-day simple moving average ($24.14). Across its 52-week range of $17.86 to $32.00, BRVE sits at the 22.5% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.41 to $23.67).

Direct Sub-Reports: BRVE RQD Cockpit BRVE 12M Forecast BRVE Earnings & Move BRVE Dividends & DRIP BRVE Insiders & 13F BRVE Whale Options BRVE Profit Sankey BRVE News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

BRVE — Braveheart Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Braveheart Bio Inc. (BRVE) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $21.04 (-2.18% 1D, market capitalization $1.94B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Braveheart Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile does not describe its products, customers, or revenue model. — Its market capitalization is $1.9B per the company profile. Reported revenue for FY 2025 is — ().

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Braveheart Bio Inc. (BRVE) reported $37.5M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $89.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $17.86 – $32.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is the only supply-chain-adjacent context provided.

  • Key Question #1: Can BRVE sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $37.5M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BRVE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BRVE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Braveheart Bio Inc. (BRVE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BRVE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BRVE Bull vs. Bear Conversation Board — What's Your Call at $21.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BRVE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BRVE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $27.96 (+30.0%)
📌 Pinned Debate

Balance-sheet strength (Forensic Balance Sheet pillar at 13/20, Altman Z 2.5, Piotroski F 6/9) with $89.2M in reported cash offers a re

Here is why I am bullish on BRVE here at $21.51: Balance-sheet strength (Forensic Balance Sheet pillar at 13/20, Altman Z 2.5, Piotroski F 6/9) with $89.2M in reported cash offers a resilience cushion while the stock trades below its $32 52-week high.. Compare BRVE's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $20.43 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — BRVE's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $17.64 (-18.0%)
Spot @ $21.51

Zero reported revenue, zero ROIC and zero FCF yield, combined with a 5/20 whale-flow score and a 7.6% share decline, indicate weak cash

Sitting on the sidelines or leaning short BRVE above $21.51. Zero reported revenue, zero ROIC and zero FCF yield, combined with a 5/20 whale-flow score and a 7.6% share decline, indicate weak cash generation and limited institutional support.. Until Fundamental Cash Engine (10/20) and FCF yield (0.0%) inflect higher, upside is capped near $32.00.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%